Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.31 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.31 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14407611 | 0.75 | LMNA (0.31) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL9862337 | 0.75 | L3MBTL1 (0.32) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL19338320 | 0.73 | LMNA (0.30) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL11615961 | 0.71 | L3MBTL1 (0.31) | — | |
| SCHEMBL11614064 | 0.71 | GRIN2D (0.31) | — | |
| SCHEMBL11612913 | 0.71 | — | — | |
| SCHEMBL9862195 | 0.70 | MEN1 (0.32) | LMNAMAPTMEN1ALDH1A1KMT2A | |
| SCHEMBL11613191 | 0.69 | CHRNB2 (0.30) | LMNA | |
| SCHEMBL11611984 | 0.69 | DRD2 (0.35) | — | |
| SCHEMBL12888600 | 0.69 | CXCR3 (0.38) | LMNAMAPTMEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060052365-A1 | Protease inhibitors | SMITHKLINE BEECHAM CORPORATION | 2006-03-09 | — | — | US | disclosed |
| US-4242507-A | Sulfonic acid esters | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052365-A1 | Protease inhibitors | CTSS, CTSE, CMA1 | LMNA 1372/4885MAPT 3989/4885MEN1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.